Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2010 Apr;11(6):937-45. doi: 10.1517/14656561003677382.

Castrate-resistant prostate cancer: therapeutic strategies.

Author information

  • 1University of California, Urologic Oncology, San Francisco, CA 94143, USA.Andrea.harzstark@ucsf.edu

Abstract

IMPORTANCE OF THE FIELD:

Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies.

AREAS COVERED IN THIS REVIEW:

This review will discuss recent developments, including new chemotherapies and chemotherapy regimens, antiangiogenic therapy, immunotherapy, and other new agents, such as endothelin-A receptor antagonists and clusterin inhibitors.

WHAT THE READER WILL GAIN:

The reader will gain an understanding of the therapies in development for castration-resistant disease.

TAKE HOME MESSAGE:

Therapies focused on multiple different targets are currently being studied for castrate-resistant prostate cancer.

PMID:
20307219
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk